The aim of this study was to improve understanding of smokers’ potential reactions to genetic testing for smoking-related diseases. One thousand twenty-four respondents completed a postal survey; 186were smokers. Questions addressed anticipated psychological and behavioral reactions to genetic test results using hypothetical scenarios. Of smokers, 65% anticipated being motivated to quit smoking upon receiving a positive genetic test result; 39% anticipated being demotivated by a negative result. More smokers anticipated being depressed in response to receiving a positive result for cancer than for heart disease (40% vs. 24%). Anticipated motivation was associated with higher desire to quit and lower nicotine addiction, anticipated depression with poorer understanding of genetic testing, and anticipated demotivation with lower education. Smokers who have a high desire to quit may use genetic testing as a motivational tool. Understanding of genetics may be important in determining how individuals respond to genetic tests for complex diseases.
Arnett, J. J. (2000). Optimistic bias in adolescent and adult smokers and nonsmokers. Addictive Behaviors, 25, 625-632.
2.
Audrain, J., Boyd, N. R., Roth, J., Main, D., Caporaso, N. F., & Lerman, C. (1997). Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trial. Addictive Behaviors, 22, 741-751.
3.
Bell, J. (1998). The new genetics in clinical practice. BMJ, 316, 618-620.
4.
Benhamou, S., Lee, W. J., Alexandrie, A. K., Boffetta, P., Bouchardy, C., Butkiewicz, D., et al. (2002). Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 23, 1343-1350.
5.
Burke, W., Atkins, D., Gwinn, M., Guttmacher, A., Haddow, J., Lau, J., et al. (2002). Genetic test evaluation: Information needs of clinicians, policy makers, and the public. American Journal of Epidemiology, 156, 311-318.
6.
Campbell, M., Fitzpatrick, R., Haines, A., Kinmonth, A. L., Sandercock, P., Spiegelhalter, D., et al. (2000). Framework for design and evaluation of complex interventions to improve health. BMJ, 321, 694-696.
7.
Collins, F. S., Green, E. D., Guttmacher, A. E., & Guyer, M. S. (2003). A vision for the future of genomics research. Nature, 422, 835-847.
8.
Day, I. N., & Wilson, D. I. (2001). Science, medicine, and the future: Genetics and cardiovascular risk. BMJ, 323, 1409-1412.
9.
el Zein, R., Zwischenberger, J. B., Wood, T. G., Abdel-Rahman, S. Z., Brekelbaum, C., & Au, W. W. (1997). Combined genetic polymorphism and risk for development of lung cancer. Mutation Research, 381, 189-200.
10.
Evers-Kiebooms, G., Welkenhuysen, M., Claes, E., Decruyenaere, M., & Denayer, L. (2000). The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: Implications for multidisciplinary counselling and for genetic education. Social Science & Medicine, 51, 831-841.
11.
Friedli, K., & King, M. B. (1998). Psychological treatments and their evaluation. International Review of Psychiatry, 10, 123-126.
12.
Gollust, S. E., Chandros Hull, S., & Wilfond, B. (2002). Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA, 288, 1762-1767.
13.
Helmes, A. W. (2002) Application of the protection motivation theory to genetic testing for breast cancer risk. Preventive Medicine, 35, 453-462.
14.
Houlston, R. S. (1999). Glutatione S-transferase M1 status and lung cancer risk: A meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 8, 675-682.
15.
Lader, D., & Goddard, E. (2002). Smoking related behaviour and attitudes, 2001. London: Office for National Statistics.
16.
Lerman, C., Gold, K., Audrain, J., Lin, T. H., Boyd, N. R., Orleans, C. T., et al. (1997). Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: Effects on smoking-related cognitions, emotions, and behavior change. Health Psychology, 16, 87-99.
17.
Lipkus, I. M., McBride, C. M., Pollak, K. I., Lyna, P., & Bepler, G. (2004). Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. Health Psychology, 23, 178-188.
18.
Marteau, T. M. (1999). Communicating genetic risk information. British Medical Bulletin, 55, 414-428.
19.
Marteau, T. M., & Lerman, C. (2001). Genetic risk and behavioural change. BMJ, 322, 1056-1059.
20.
McBride, C. M., Bepler, G., Lipkus, I. M., Lyna, P., Samsa, G., Albright, J., et al. (2002). Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiology, Biomarkers & Prevention, 11, 521-528.
21.
McWilliams, J. E., Sanderson, B. J., Harris, E. L., Richert-Boe, K. E., & Henner, W. D. (1995). Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention, 4, 589-594.
22.
Meiser, B., & Dunn, S. (2000). Psychological impact of genetic testing for Huntington’s disease: An update of the literature. Journal of Neurology, Neurosurgery, and Psychiatry, 69, 574-578.
23.
Rogers, R. W. (1975). A protection motivation theory of fear appeals and attitude change. Journal of Psychology, 91, 93-114.
24.
Rogers, R. W. (1983). Cognitive and physiological processes in fear appeals and attitude change: A revised theory of protection motivation. In J. T. Cacioppo & R. E. Petty (Eds.), Social psychophysiology: A source book (pp. 153-176). New York: Guilford.
25.
Rosenstock, I. M. (1974). Historical origins of the Health Belief Model. Health Education Monographs, 2, 1-8.
26.
Rostami-Hodjegan, A., Lennard, M. S., Woods, H. F., & Tucker, G. T. (1998). Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics, 8, 227-238.
27.
Russell, M. A. (1971). Cigarette dependence. I. Nature and classification. BMJ, 2, 330-331.
28.
Sanderson, S. C., Wardle, J., Jarvis, M. J., & Humphries, S. E. (2004). Public interest in genetic testing for susceptibility to heart disease and cancer: A population-based survey in the UK. Preventive Medicine, 39, 458-464.
29.
Sanderson, S. C., Wardle, J., & Michie, S. (2005). The effects of a genetic information leaflet on public attitudes towards genetic testing. Public Understanding of Science, 14, 213-224.
30.
Scheier, M. F., & Carver, C. S. (1985). Optimism, coping and health: Assessment and implications of generalized outcome expectancies. Health Psychology, 4, 219-247.
31.
Scheier, M. F., Carver, C. S., & Bridges, M. W. (1994). Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test. Journal of Personality and Social Psychology, 67, 1063-1078.
32.
Schwarzer, R. (1992). Self-efficacy in the adoption and maintenance of health behaviors: Theoretical approaches and a new model. In R. Schwarzer (Ed.), Thought control of action (pp. 217-242). Washington, DC: Hemisphere.
33.
Stephenson, J., & Imrie, J. (1998). Why do we need randomised controlled trials to assess behavioural interventions?BMJ, 316, 611-613.
34.
Turk-Charles, S., Meyerowitz, B. E., & Gatz, M. (1997). Age differences in information-seeking among cancer patients. International Journal of Aging and Humand Development, 45, 85-98.
35.
U.K. Advisory Committee on Genetic Testing. (1998). Report on genetic testing for late onset disorders. London: Health Departments of the United Kingdom.
36.
Vineis, P., Marinelli, D., Autrup, H., Brockmoller, J., Cascorbi, I., Daly, A. K., et al. (2001). Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies. Cancer Epidemiology, Biomarkers and Prevention, 10, 1249-1252.
37.
Wang, C., Gonzalez, R., & Merajver, S. D. (2004). Assessment of genetic testing and related counselling services: Current research and future directions. Social Science and Medicine, 58, 1427-1442.
38.
Weinman, J., Petrie, K., Moss-Morris, R., & Horne, R. (1996). The Illness Perception Questionnaire: A new method for assessing the cognitive representations of illness. Psychology and Health, 11, 114-129.
39.
Witte, K. (1992). Putting the fear back into fear appeals: The Extended Parallel Process Model. Communication Monographs, 59, 329-349.
40.
Witte, K., & Allen, M. (2000). A meta-analysis of fear appeals: Implications for effective public health campaigns. Health Education & Behavior, 27, 591-615.
